EVAR LOMBARD MEDICAL

Lombard Medical’s CEO Steps Down

Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that Simon Hubbert has stepped down from his position as CEO on April 18 after serving in the role for more than six years. A search is underway for a successor and an announcement is expected in due course.

Hubbert joined Lombard during 2010 and was appointed CEO in 2011. During Hubbert’s tenure, Lombard achieved several significant milestones, including US FDA and Japan PMDA approval for Aorfix™, its flagship product. In Japan, Aorfix now holds an approximate eight percent market share. In 2014, Lombard consummated a NASDAQ IPO, and in 2015, acquired pre-revenue stage Altura® Medical. Most recently, in December 2016, Lombard executed a strategic alliance with one of China’s largest medical devices companies, MicroPort Scientific Corporation.

“Simon made many significant contributions during his six years as CEO of Lombard including expanding the Company’s product portfolio and geographic reach,” said Raymond W. Cohen, Chairman of the Board of Directors. “On behalf of the board and shareholders, we thank Simon for his contributions and diligent efforts during a time of significant change in the endovascular aneurysm repair market. We wish him well in his future endeavors.”

About Lombard Medical, Inc.

Lombard Medical, Inc., based in Oxfordshire, U.K., develops, manufactures and markets an innovative range of minimally invasive abdominal aortic aneurysm endovascular repair products. The Company has global regulatory approval for Aorfix, an endovascular stent graft that has been specifically designed to treat patients with aortic neck angulation up to 90 degrees. Lombard also manufactures and markets CE-marked Altura, an ultra-low profile endovascular stent graft that offers a simple and predictable solution for the treatment of standard AAA anatomies. The Altura endograft system is sold in select European markets. For more information, please visit www.lombardmedical.com.

EN
18/04/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LOMBARD MEDICAL

 PRESS RELEASE

Lombard Medical Reports First Half and Third Quarter 2017 Financial Re...

OXFORDSHIRE, U.K.--(BUSINESS WIRE)-- Lombard Medical, Inc. (NASDAQ: EVAR), a medical device company focused on endovascular aneurysm repair of abdominal aortic aneurysms (AAA), today reported unaudited year-to-date financial results for the first nine months ended September 30, 2017. 2017 Operational Highlights Appointment of Kurt Lemvigh as CEO, April 2017 Appointment of Richard Peace as Finance Director, May 2017 Appointment of Jonathan Hornsby as Vice President, Sales & Marke...

 PRESS RELEASE

Lombard Medical Announces Shares to Trade on OTCQX

OXFORDSHIRE, U.K.--(BUSINESS WIRE)-- Lombard Medical, Inc. (Nasdaq: EVAR), a medical device company focused on endovascular aneurysm repair of abdominal aortic aneurysms (AAA), today announced that it has notified Nasdaq of its intention to voluntarily delist the Company’s shares from the Nasdaq Capital Market (“Nasdaq”) and transfer its listing to the OTCQX. Lombard anticipates that its common shares will trade under its existing ticker symbol EVAR on the OTCQX Market effective as of the market open on November 9, 2017. ...

 PRESS RELEASE

Lombard Medical Announces First Patient Enrolled and Treated in the AL...

OXFORDSHIRE, U.K.--(BUSINESS WIRE)-- Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that it has enrolled and treated the first patient in its global registry to evaluate its Altura® Endograft System. The ALTITUDE registry (ALTura Impact on the Treatment of Abdominal Aortic Aneurysms Using a Novel D-stent EVAR Design) is being conducted across a range of UK and international clinical centers to evaluate the use of the Altura Endograf...

 PRESS RELEASE

Lombard Medical’s Endovascular Product Portfolio Presented at Scient...

OXFORDSHIRE, U.K.--(BUSINESS WIRE)-- Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that its portfolio of endovascular stent graft systems, Altura® and Aorfix™, were featured in scientific presentations at the 39th annual Charing Cross International Symposium in London on April 25 - 26. Altura Presentations Altura clinical data combined from two prospective international multicentre studies were presented at Charing Cross i...

 PRESS RELEASE

Lombard Medical Appoints New CEO

OXFORDSHIRE, England--(BUSINESS WIRE)-- Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that Kurt Lemvigh has been appointed as its new Chief Executive Officer, effective immediately. Lemvigh is a veteran medical device executive with over 30 years of experience creating profitable growth. He currently resides in the U.K. and has held senior sales, marketing and operational positions at various public and private companies including ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch